Literature DB >> 26680778

High residual platelet reactivity (HRPR) for adenosine diphosphate (ADP) stimuli is a determinant factor for long-term outcomes in acute ischemic stroke with anti-platelet agents: The meaning of HRPR after ADP might be more prominent in large atherosclerotic infarction than other subtypes of AIS.

Jae-Kwan Cha1,2, Hyun-Seok Park3, Hyun-Wook Nah3, Dae-Hyun Kim3, Myong-Jin Kang3, Jae-Hyung Choi3, Jae-Taeck Huh3, Hyun-Kyung Suh4.   

Abstract

High residual platelet activation (HRPA) after ADP stimuli has associated with recurrent vascular events in acute atherothrombosis with the use of antiplatelet agents (APAs). However, there has been little evidence supporting this association in acute ischemic stroke (AIS). In this study, we evaluated the influences of HRPR after ADP stimuli on the 1-year incidence of recurrent cardiovascular events and mortality in AIS with APAs. We conducted an observational, referral center cohort study on 968 AIS patients with APAs from January 2010 to December 2013 who were evaluated using optical platelet aggregometry (OPA). All patients received the dual APA combination of aspirin and clopidogrel or aspirin alone. We evaluated their platelet function 5 days after hospital admission using OPA. HRPR after ADP stimuli was defined as platelet aggregation of 70 % or greater according to OPA after 10 µM ADP stimuli. The primary endpoint was a composite of all causes of death, myocardial infarction, and stroke at the 1-year follow-up. The secondary endpoints were each component of the primary endpoint. The event rate of primary endpoint was 11.3 % (109/968). Its rate was significantly higher in the patients with HRPR (16.7 %) than in those without (9.7 %). HPRP was independently associated with the primary endpoint (OR = 1.97, CI 1.22-3.18, p < 0.01). According to the AIS subtype, the presence of HRPR was independently significant for the occurrence of the primary endpoint in the large artery atherosclerosis (LAA) subtype only (OR = 2.26, CI 1.15-4.45, p = 0.02). In this study, the presence of HRPR after ADP stimuli is associated with a poor long-term outcome after acute ischemic stroke. In particular, the influence of this factor might be more prominent in LAA compared with other types of AIS.

Entities:  

Keywords:  Acute ischemic stroke; Aspirin; Clopidogrel; Platelet aggregation

Mesh:

Substances:

Year:  2016        PMID: 26680778     DOI: 10.1007/s11239-015-1304-5

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  29 in total

1.  Leukocyte-platelet aggregates in acute and subacute ischemic stroke.

Authors:  L Marquardt; C Anders; F Buggle; F Palm; P Hellstern; A J Grau
Journal:  Cerebrovasc Dis       Date:  2009-07-16       Impact factor: 2.762

2.  Detection of paroxysmal atrial fibrillation by 30-day event monitoring in cryptogenic ischemic stroke: the Stroke and Monitoring for PAF in Real Time (SMART) Registry.

Authors:  Alexander C Flint; Nader M Banki; Xiushui Ren; Vivek A Rao; Alan S Go
Journal:  Stroke       Date:  2012-08-07       Impact factor: 7.914

Review 3.  Suboptimal response to clopidogrel: a genetic risk factor for recurrent ischaemic stroke.

Authors:  Daniel Bennett; Bernard Yan
Journal:  J Clin Neurosci       Date:  2013-04-22       Impact factor: 1.961

4.  Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.

Authors:  Yongjun Wang; Yilong Wang; Xingquan Zhao; Liping Liu; David Wang; Chunxue Wang; Chen Wang; Hao Li; Xia Meng; Liying Cui; Jianping Jia; Qiang Dong; Anding Xu; Jinsheng Zeng; Yansheng Li; Zhimin Wang; Haiqin Xia; S Claiborne Johnston
Journal:  N Engl J Med       Date:  2013-06-26       Impact factor: 91.245

5.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

Authors:  S Yusuf; F Zhao; S R Mehta; S Chrolavicius; G Tognoni; K K Fox
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

6.  Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.

Authors:  Paul A Gurbel; Kevin P Bliden; Joseph DiChiara; Justin Newcomer; Willy Weng; Nagaraj K Neerchal; Tania Gesheff; Srivasavi K Chaganti; Amena Etherington; Udaya S Tantry
Journal:  Circulation       Date:  2007-06-11       Impact factor: 29.690

7.  A comparative study of dual versus monoantiplatelet therapy in patients with acute large-artery atherosclerosis stroke.

Authors:  Xingyang Yi; Jing Lin; Chun Wang; Biao Zhang; Wanzhang Chi
Journal:  J Stroke Cerebrovasc Dis       Date:  2014-04-13       Impact factor: 2.136

8.  Increased sensitivity to ADP-aggregation in aspirin treated patients with recurrent ischemic stroke?

Authors:  I Mattiasson; S Lethagen; A Hillarp
Journal:  Int Angiol       Date:  2003-09       Impact factor: 2.789

9.  A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.

Authors:  Patricia A Gum; Kandice Kottke-Marchant; Patricia A Welsh; Jennifer White; Eric J Topol
Journal:  J Am Coll Cardiol       Date:  2003-03-19       Impact factor: 24.094

10.  MRI-based Algorithm for Acute Ischemic Stroke Subtype Classification.

Authors:  Youngchai Ko; SooJoo Lee; Jong-Won Chung; Moon-Ku Han; Jong-Moo Park; Kyusik Kang; Tai Hwan Park; Sang-Soon Park; Yong-Jin Cho; Keun-Sik Hong; Kyung Bok Lee; Jun Lee; Dong-Eog Kim; Dae-Hyun Kim; Jae-Kwan Cha; Joon-Tae Kim; Jay Chol Choi; Dong-Ick Shin; Ji Sung Lee; Juneyoung Lee; Kyung-Ho Yu; Byung-Chul Lee; Hee-Joon Bae
Journal:  J Stroke       Date:  2014-09-30       Impact factor: 6.967

View more
  3 in total

Review 1.  The Importance of Platelets Response during Antiplatelet Treatment after Ischemic Stroke-Between Benefit and Risk: A Systematic Review.

Authors:  Joanna Sikora; Aleksandra Karczmarska-Wódzka; Joanna Bugieda; Przemysław Sobczak
Journal:  Int J Mol Sci       Date:  2022-01-18       Impact factor: 5.923

2.  Dual Therapy with Aspirin and Cilostazol May Improve Platelet Aggregation in Noncardioembolic Stroke Patients: A Pilot Study.

Authors:  Yoichi Ohnuki; Yuko Ohnuki; Saori Kohara; Mie Shimizu; Shunya Takizawa
Journal:  Intern Med       Date:  2017-06-01       Impact factor: 1.271

3.  PIK3CG single nucleotide polymorphisms are associated with poor responsiveness to clopidogrel and increased risk of ischemia in patients with coronary heart disease.

Authors:  Ke-Cheng Li; Shu-Hong Yu; Bao-Zhong Zhuge
Journal:  Medicine (Baltimore)       Date:  2017-09       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.